Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 95


Randomized Phase III Trial of Standard Therapy Plus Low Molecular Weight Heparin in Patients With Lung Cancer: FRAGMATIC Trial.

Macbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K, Knoyle D, Linnane S, Longo M, Moore B, Woll PJ, Appel W, Dickson J, Ferry D, Brammer C, Griffiths G.

J Clin Oncol. 2016 Feb 10;34(5):488-94. doi: 10.1200/JCO.2015.64.0268. Epub 2015 Dec 23.


The relationship between smoking and quality of life in advanced lung cancer patients: a prospective longitudinal study.

Danson SJ, Rowland C, Rowe R, Ellis S, Crabtree C, Horsman JM, Wadsley J, Hatton MQ, Woll PJ, Eiser C.

Support Care Cancer. 2015 Sep 12. [Epub ahead of print]


Bone-targeted agents in the treatment of lung cancer.

Silva SC, Wilson C, Woll PJ.

Ther Adv Med Oncol. 2015 Jul;7(4):219-28. doi: 10.1177/1758834015582178. Review.


Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).

O'Brien ME, Gaafar R, Hasan B, Menis J, Cufer T, Popat S, Woll PJ, Surmont V, Georgoulias V, Montes A, Blackhall F, Hennig I, Schmid-Bindert G, Baas P; EORTC-LCG.

Eur J Cancer. 2015 Aug;51(12):1511-28. doi: 10.1016/j.ejca.2015.04.026. Epub 2015 Jun 11.


Angiogenic growth factor expression in benign and malignant vascular tumours.

Young RJ, Fernando M, Hughes D, Brown NJ, Woll PJ.

Exp Mol Pathol. 2014 Aug;97(1):148-53. doi: 10.1016/j.yexmp.2014.06.010. Epub 2014 Jun 28.


Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium.

Zhang LR, Morgenstern H, Greenland S, Chang SC, Lazarus P, Teare MD, Woll PJ, Orlow I, Cox B; Cannabis and Respiratory Disease Research Group of New Zealand, Brhane Y, Liu G, Hung RJ.

Int J Cancer. 2015 Feb 15;136(4):894-903. doi: 10.1002/ijc.29036. Epub 2014 Jun 30.


Quality of life, support and smoking in advanced lung cancer patients: a qualitative study.

Rowland C, Danson SJ, Rowe R, Merrick H, Woll PJ, Hatton MQ, Wadsley J, Ellis S, Crabtree C, Horsman JM, Eiser C.

BMJ Support Palliat Care. 2014 Apr 30. doi: 10.1136/bmjspcare-2013-000589. [Epub ahead of print]


Vascular-targeted agents for the treatment of angiosarcoma.

Young RJ, Woll PJ, Staton CA, Reed MW, Brown NJ.

Cancer Chemother Pharmacol. 2014 Feb;73(2):259-70. doi: 10.1007/s00280-013-2345-0. Epub 2013 Nov 20.


Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.

Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, Yeh H.

Support Care Cancer. 2014 Mar;22(3):679-87. doi: 10.1007/s00520-013-2022-1. Epub 2013 Oct 26.


Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.

Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, Solal-Celigny P, Rodriguez G, Krzakowski M, Mehta ND, Lipton L, García-Sáenz JA, Pereira JR, Prabhash K, Ciuleanu TE, Kanarev V, Wang H, Balakumaran A, Jacobs I.

J Thorac Oncol. 2012 Dec;7(12):1823-9. doi: 10.1097/JTO.0b013e31826aec2b.


First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.

Lee SM, Khan I, Upadhyay S, Lewanski C, Falk S, Skailes G, Marshall E, Woll PJ, Hatton M, Lal R, Jones R, Toy E, Chao D, Middleton G, Bulley S, Ngai Y, Rudd R, Hackshaw A, Boshoff C.

Lancet Oncol. 2012 Nov;13(11):1161-70. doi: 10.1016/S1470-2045(12)70412-6. Epub 2012 Oct 16.


Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931.

Kasper B, Ouali M, van Glabbeke M, Blay JY, Bramwell VH, Woll PJ, Hohenberger P, Schöffski P.

Eur J Cancer. 2013 Jan;49(2):449-56. doi: 10.1016/j.ejca.2012.08.007. Epub 2012 Sep 10.


Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.

Woll PJ, Reichardt P, Le Cesne A, Bonvalot S, Azzarelli A, Hoekstra HJ, Leahy M, Van Coevorden F, Verweij J, Hogendoorn PC, Ouali M, Marreaud S, Bramwell VH, Hohenberger P; EORTC Soft Tissue and Bone Sarcoma Group and the NCIC Clinical Trials Group Sarcoma Disease Site Committee.

Lancet Oncol. 2012 Oct;13(10):1045-54. doi: 10.1016/S1470-2045(12)70346-7. Epub 2012 Sep 4.


Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer.

Manegold C, Vansteenkiste J, Cardenal F, Schuette W, Woll PJ, Ulsperger E, Kerber A, Eckmayr J, von Pawel J.

Invest New Drugs. 2013 Feb;31(1):175-82. doi: 10.1007/s10637-012-9842-6. Epub 2012 Jul 3.


Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium.

Coté ML, Liu M, Bonassi S, Neri M, Schwartz AG, Christiani DC, Spitz MR, Muscat JE, Rennert G, Aben KK, Andrew AS, Bencko V, Bickeböller H, Boffetta P, Brennan P, Brenner H, Duell EJ, Fabianova E, Field JK, Foretova L, Friis S, Harris CC, Holcatova I, Hong YC, Isla D, Janout V, Kiemeney LA, Kiyohara C, Lan Q, Lazarus P, Lissowska J, Le Marchand L, Mates D, Matsuo K, Mayordomo JI, McLaughlin JR, Morgenstern H, Müeller H, Orlow I, Park BJ, Pinchev M, Raji OY, Rennert HS, Rudnai P, Seow A, Stucker I, Szeszenia-Dabrowska N, Dawn Teare M, Tjønnelan A, Ugolini D, van der Heijden HF, Wichmann E, Wiencke JK, Woll PJ, Yang P, Zaridze D, Zhang ZF, Etzel CJ, Hung RJ.

Eur J Cancer. 2012 Sep;48(13):1957-68. doi: 10.1016/j.ejca.2012.01.038. Epub 2012 Mar 19.


Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.

Young RJ, Tin AW, Brown NJ, Jitlal M, Lee SM, Woll PJ.

Br J Cancer. 2012 Mar 13;106(6):1153-9. doi: 10.1038/bjc.2012.50. Epub 2012 Feb 21.


Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.

J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22.



Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ.

Lancet Oncol. 2010 Oct;11(10):983-91. doi: 10.1016/S1470-2045(10)70023-1. Epub 2010 May 25. Review.


Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer.

Lee SM, Rudd R, Woll PJ, Ottensmeier C, Gilligan D, Price A, Spiro S, Gower N, Jitlal M, Hackshaw A.

J Clin Oncol. 2009 Nov 1;27(31):5248-54. doi: 10.1200/JCO.2009.21.9733. Epub 2009 Sep 21.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk